Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Steven A. Johnsen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1198-5805; OpenAlex author ID A5059210191. Sources: OpenAlex.

Their work

Papers
24 (first author 5, last author 7)
Trials
0
Grants
0
Labs led
2
Collaborators
98
Papers, trials and grants by year

2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: 2 papers · 2020: 2 papers · 2021: 4 papers · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: 3 papers · 2026: 4 papers

Papers 24

  1. Epigenetic context defines the transcriptional activity of canonical and noncanonical NF-κB signaling in pancreatic cancer. Last author DOI 10.1038/s41420-026-03019-9↗
  2. Epigenetic and transcriptional control of classical and basal-like cell states in pancreatic ductal adenocarcinoma. First author DOI 10.1093/gastro/goag028↗
  3. KLF5 controls subtype-independent highly interactive enhancers in pancreatic cancer to regulate cell survival. Last author DOI 10.1126/sciadv.aea2106↗
  4. GSK3βhigh/NFATc1high subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induction of homologous recombination repair. Co-author DOI 10.1136/gutjnl-2025-336227↗
  5. Patient-derived tumor organoids highlight the potential of precision medicine in managing pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.35443↗
  6. Therapeutic targeting of FOSL1 and RELA-dependent transcriptional mechanisms to suppress pancreatic cancer metastasis. Last author DOI 10.1038/s41419-025-07810-x↗
  7. Glucocorticoid receptor suppresses GATA6-mediated RNA polymerase II pause release to modulate classical subtype identity in pancreatic cancer. Last author DOI 10.1136/gutjnl-2024-334374↗
  8. An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic Cancer Guides Rational Therapies. Co-author DOI 10.1053/j.gastro.2023.10.026↗
  9. Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation. Co-author DOI 10.1186/s13148-024-01623-z↗
  10. Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancer. Last author DOI 10.1136/gutjnl-2022-328154↗
  11. Identification of a ΔNp63-Dependent Basal-Like A Subtype-Specific Transcribed Enhancer Program (B-STEP) in Aggressive Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1541-7786.mcr-22-0916↗
  12. New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting. Co-author DOI 10.1053/j.gastro.2021.04.082↗
  13. STIM1 Mediates Calcium-Dependent Epigenetic Reprogramming in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-20-2874↗
  14. Telomerase and Pluripotency Factors Jointly Regulate Stemness in Pancreatic Cancer Stem Cells. Co-author DOI 10.3390/cancers13133145↗
  15. Store-Operated Calcium Entry: Shaping the Transcriptional and Epigenetic Landscape in Pancreatic Cancer. First author DOI 10.3390/cells10050966↗
  16. Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33137↗
  17. EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6. Co-author DOI 10.1158/0008-5472.can-20-0672↗
  18. Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites. Co-author DOI 10.1016/j.ebiom.2019.01.037↗
  19. Aberrant NFATc1 signaling counteracts TGFβ-mediated growth arrest and apoptosis induction in pancreatic cancer progression. Co-author DOI 10.1038/s41419-019-1682-2↗
  20. DeltaNp63-dependent super enhancers define molecular identity in pancreatic cancer by an interconnected transcription factor network. First author DOI 10.1073/pnas.1812915116↗
  21. Epigenetic Targeting of Aberrant Transcriptional Modulation in Pancreatic Cancer First author DOI 10.3390/epigenomes2020008↗
  22. Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner. Last author DOI 10.1093/nar/gkx212↗
  23. Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon? First author DOI 10.1136/gutjnl-2016-312539↗
  24. Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer. Co-author DOI 10.1093/jnci/djv387↗

Closest collaborators

The 25 strongest of 98 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elisabeth Heßmann · 12 shared papers, 2017–2026 · strength 1.44
  2. Feda H. Hamdan · 10 shared papers, 2018–2024 · strength 1.34
  3. Amro M. Abdelrahman · 6 shared papers, 2023–2026 · strength 1.20
  4. Mark Joseph Truty · 6 shared papers, 2023–2026 · strength 1.20
  5. Zeynab Najafova · 8 shared papers, 2017–2026 · strength 1.17
  6. Volker Ellenrieder · 9 shared papers, 2017–2026 · strength 1.11
  7. Christina Parassiadis · 2 shared papers, 2025–2026 · strength 0.82
  8. Ana P. Kutschat · 5 shared papers, 2021–2025 · strength 0.79
  9. Jochen Gaedcke · 7 shared papers, 2016–2025 · strength 0.78
  10. Jens Thomas Siveke · 7 shared papers, 2017–2024 · strength 0.77
  11. Joana E. Aggrey-Fynn · 4 shared papers, 2023–2026 · strength 0.77
  12. Xin Wang · 5 shared papers, 2020–2025 · strength 0.65
  13. Thomas L. Ekstrom · 3 shared papers, 2023–2026 · strength 0.56
  14. Shiv K. Singh · 4 shared papers, 2020–2026 · strength 0.51
  15. Stephan A. Hahn · 4 shared papers, 2020–2024 · strength 0.49
  16. Günter Schneider · 3 shared papers, 2021–2026 · strength 0.43
  17. Ulrich Sax · 2 shared papers, 2024–2026 · strength 0.34
  18. Albrecht Neeße · 3 shared papers, 2019–2024 · strength 0.29
  19. Jennifer A. Yonkus · 2 shared papers, 2023 · strength 0.27
  20. Rondell Patrell Graham · 2 shared papers, 2023 · strength 0.27
  21. Roberto Alva‐Ruiz · 2 shared papers, 2023 · strength 0.27
  22. Marie C. Hasselluhn · 2 shared papers, 2019–2024 · strength 0.26
  23. Sven‐Thorsten Liffers · 2 shared papers, 2020–2024 · strength 0.26
  24. Marija Trajkovic‐Arsic · 2 shared papers, 2020–2024 · strength 0.26
  25. Thilo Hackert · 2 shared papers, 2016–2025 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.